301258.SHE Suzhou Fushilai Pharmaceutical Co. Ltd.
- Market cap
- CNY 2.05B
- P/E
- -
- P/B
- 1.14x
- ROE
- -2.8%
- Dividend yield
- 0.40%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.
Is 301258.SHE undervalued?
Graham numberThe Graham number of Suzhou Fushilai Pharmaceutical Co. Ltd. cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Suzhou Fushilai Pharmaceutical Co. Ltd. fundamental analysis
No fundamental analysis for Suzhou Fushilai Pharmaceutical Co. Ltd. yet.
Suzhou Fushilai Pharmaceutical Co. Ltd. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products…
Full company profileSuzhou Fushilai Pharmaceutical Co. Ltd. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 3 quarters up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Suzhou Fushilai Pharmaceutical Co. Ltd. annual financial statements (CNY; K = thousand, M = million, B = billion, T = trillion)
| Item | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||
| Revenue | 452M | 477M | 522M | 568M | 489M | 429M | 433M | 353M |
| Gross Profit | 226M | 225M | 210M | 257M | 188M | 84.3M | 72.2M | 37.3M |
| Operating Income | 168M | 168M | 145M | 171M | 96.2M | -1.23M | -8.10M | -42.5M |
| EBITDA | 187M | 181M | 185M | 255M | 185M | 67.3M | 123M | -58.3M |
| Net Income | 146M | 141M | 120M | 177M | 112M | 16.4M | 64.3M | -50.8M |
| EPS | 2.12 | 2.05 | 1.75 | 1.93 | 1.22 | 0.18 | 0.70 | -0.55 |
| Balance Sheet | ||||||||
| Total Assets | 751M | 788M | 970M | 2.10B | 2.12B | 2.09B | 2.12B | 2.00B |
| Total Liabilities | 169M | 166M | 227M | 212M | 170M | 201M | 255M | 192M |
| Shareholders' Equity | 582M | 623M | 743M | 1.89B | 1.95B | 1.89B | 1.86B | 1.81B |
| Cash & Short-term Investments | 195M | 98.1M | 332M | 260M | 350M | 225M | 362M | 495M |
| Cash Flow | ||||||||
| Operating Cash Flow | 151M | 167M | 200M | 151M | 94.8M | 47.1M | 66.6M | - |
| Capital Expenditure | 70.9M | 65.7M | 80.7M | 50.1M | 41.6M | 105M | 146M | 110M |
| Free Cash Flow | 79.6M | 101M | 119M | 101M | 53.1M | -58.2M | -79.9M | -145M |
| Ratios | ||||||||
| ROE | 25.0% | 22.7% | 16.2% | 9.4% | 5.8% | 0.9% | 3.4% | -2.8% |
| ROA | 19.4% | 17.9% | 12.4% | 8.4% | 5.3% | 0.8% | 3.0% | -2.5% |
| Net Profit Margin | 32.2% | 29.6% | 23.0% | 31.2% | 22.9% | 3.8% | 14.9% | -14.4% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Suzhou Fushilai Pharmaceutical Co. Ltd. dividends
- Dividend yield
- 0.40%
- Forward dividend
- 0.22 CNY
- Payout ratio
- 12.9%
- Ex-dividend date
- May 29, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | CNY 8.26M | 0.09 | 12.9% |
| 2024 | CNY 55.0M | 0.60 | 335.1% |
| 2023 | CNY 53.2M | 0.58 | 47.4% |
| 2022 | CNY 36.9M | 0.40 | 20.8% |
| 2021 | CNY 436K | 0.01 | 0.4% |
| 2020 | CNY 100M | 1.46 | 71.2% |
| 2019 | CNY 49.5M | 0.72 | 34.0% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Suzhou Fushilai Pharmaceutical Co. Ltd.
- Insiders 66.07%
- Institutions 2.06%
- Public & others 31.87%
- Shares outstanding 91.7M
- Free float 31.4M
Suzhou Fushilai Pharmaceutical Co. Ltd. company profile
- Company name
- Suzhou Fushilai Pharmaceutical Co. Ltd.
- Ticker
- 301258.SHE
- ISIN
- CNE1000058W2
- Exchange
- Shenzhen Stock Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 540
- Fiscal year end
- December
- Address
- No.16 Haiwang Road, Changshu, China, 215500
- Phone
- 86 51 2528 35990
- Website
- fuslai.com
About Suzhou Fushilai Pharmaceutical Co. Ltd.
Suzhou Fushilai Pharmaceutical Co., Ltd., together with its subsidiaries, engages in the research, development, production, and sale of pharmaceutical intermediates, active pharmaceutical ingredients (APIs), and health care raw materials in China and internationally. The company offers lipoic acid products comprising granular alpha lipoic acid, R-lipoic acid, r-lipoic acid tromethamine salt, and 6,8-dichlorooctanoic acid ethyl ester; L-carnosine; phosphatidylcholine products, which include glycerylphosphatidylcholine; and erelcoxib API, a nonsteroidal anti-inflammatory analgesic used to relieve the pain symptoms of osteoarthritis. Its products are used in medicines, dietary supplements, and cosmetics applications. The company also engages in research and experimental development and capital market activities. Suzhou Fushilai Pharmaceutical Co., Ltd. was founded in 2000 and is based in Changshu, China.
Suzhou Fushilai Pharmaceutical Co. Ltd. management
2- Mr. Xiangyun QianChairman & GM · born 1969
- Mr. Aijin BianDeputy GM, Board Secretary, Financial Director, Head of Accounting Agency & Director · born 1985